baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Nektar Therapeutics/ US6402681083 /

2024-05-10 10:00:00 PM	Chg. +0.1600	Volume	Bid1:02:26 AM	Ask1:02:26 AM	Market Capitalization	Dividend Y.	P/E Ratio
1.7600USD	+10.00%	2.36 mill. Turnover: 3.96 mill.	1.7900Bid Size: 24,900	1.8300Ask Size: 100	322.6 mill.USD	0.00%	-

GlobeNewswire 05-09 ACELYRIN, INC. Announces Leadership Transition

GlobeNewswire 05-09 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 04-24 Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI...

GlobeNewswire 03-04 Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

GlobeNewswire 2023-12-29 Chimerix Appoints Lisa Decker to Board of Directors

GlobeNewswire 2023-12-28 Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Myriam J. C...

GlobeNewswire 2023-11-13 Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer

GlobeNewswire 2023-09-15 Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

GlobeNewswire 2022-03-08 Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meetin...

GlobeNewswire 2022-03-08 Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the...

GlobeNewswire 2022-02-14 Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference

GlobeNewswire 2022-02-11 Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in co...

GlobeNewswire 2021-12-28 Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2...

GlobeNewswire 2021-11-22 Virion Therapeutics, LLC Announces the Appointment of Sue Currie, Ph.D. as Chief Operating Officer

GlobeNewswire 2021-11-15 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and...

GlobeNewswire 2021-11-03 Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Exe...

GlobeNewswire 2021-10-04 Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

GlobeNewswire 2021-06-15 Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer

GlobeNewswire 2021-05-12 Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer

GlobeNewswire 2021-04-27 VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors

GlobeNewswire 2021-04-15 ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO

GlobeNewswire 2021-03-22 Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Developm...

GlobeNewswire 2021-03-15 IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer

GlobeNewswire 2021-02-25 Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutic...

GlobeNewswire 2021-01-20 ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTE...

Nektar Therapeutics/ US6402681083 /

If you wish to receive reply to your feedback, please provide your email address.